Guido Ghilardi

TL;DR: The majority of very low-risk patients remained free of progression after treatment and their hazard of relapse decreased after 4 years from FCR, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group.

TL;DR: The role of the intestinal microbiome on clinical outcomes after anti-CD19 CAR T cell therapy in patients with B cell malignancies was investigated in a multicenter study as mentioned in this paper .

TL;DR: Daratumumab is a very effective and safe treatment option in AL patients with relapsed/refractory disease and high disease burden at diagnosis, and leads to rapid disease control and improvement of organ function.

TL;DR: In this article , the safety and efficacy of bendamustine lymphodepletion using either fludarabine/cyclophosphamide (n = 42) or bendhamustine (n= 90) before tisagenlecleucel in two cohorts of patients with relapsed or refractory large B-cell lymphomas treated consecutively at three academic institutions in the United States and Europe (University of Pennsylvania, n = 90; Oregon Health & Science University, N = 35).

TL;DR: Given the paucity of safety data for venetoclax in patients with AL amyloidosis and renal involvement, the patient was considered too frail to undergo high-dose melphalan therapy and autologous stem cell transplantation and chose a weekly ramp-up scheme starting with 20mg daily up to 400mg daily.